Liver structure and function in cholelithiasis: Effect of chenodeoxycholic acid

Bell, G. D.; Mok, Henry; Thwe, M.; Murphy, Gérard M.; Henry, K.; Dowling, R. H.

doi:10.1136/gut.15.3.165

Cited by 70 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of more importance are the hepatic effects of chenodeoxycholic acid which usually occur on less than the maximal tolerated dose. Since its toxicity is probably dose related, lower doses are preferable (Bell, Mok, Thwe, Murphy, Henry & Dowling, 1974). This study demonstrated more change in 'liver function' tests on clofibrate than CDCA.…”

Section: Discussionmentioning

confidence: 61%

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

Bateson¹,

Maclean²,

Evans³

et al. 1978

Brit J Clinical Pharma

View full text Add to dashboard Cite

I Ten consecutive patients with hypertriglyceridaemia who adhered to a low carbohydrate diet without complete control of serum triglycerides were started on chenodeoxycholic acid 750 mg daily and followed monthly for 6 months. Nine of these patients were then followed for a further month on placebo capsules and thereafter monthly for a further 6 months on clofibrate 2 g daily. 2 The mean serum triglyceride level fell by 36% after dietary treatment alone (P <0.05) and by 47% from initial values on diet plus chenodeoxycholic acid (P < 0.01). In the nine patients who proceeded to clofibrate therapy there was a rise in triglyceride levels on placebo capsules to the level achieved by diet alone, and a further fall on diet plus clofibrate of 47% of initial values (P < 0.05). 3 Chenodeoxycholic acid therapy is effective in the management of hypertriglyceridaemia not completely cured by dietary measures, and may be as efficacious as clofibrate.

show abstract

Section: Discussionmentioning

confidence: 61%

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

Bateson¹,

Maclean²,

Evans³

et al. 1978

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…As a result of these reports, European studies were stopped in 1973. Report of the primate toxicity provided a justifi cation for liver biopsies in the patients when therapy was stopped ( 413 ). An international registry of biopsies was set up, and a careful review of the biopsy histology showed no important histological changes.…”

Section: Acceleration Of Dissolution By Extracorporeal Shockwave Lithmentioning

confidence: 99%

Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades

Hofmann

Hagey

2014

Journal of Lipid Research

303

284

View full text Add to dashboard Cite

conceptions are rare, and provocative judgments stand the test of time. Let us also hope that this effort will be both useful and entertaining. Each of the topics discussed merits at least a full length article, so there will be, of necessity in many instances, consideration of only what we perceive to be the highlights. THE EBB AND FLOW OF MEDICAL INTEREST IN BILE ACIDSAfter the elucidation of the true chemical structure of bile acids in 1932 (see below), there was little interest in bile acids in the Western world. One exception to this statement was the laboratory of Siegfried Thannhauser, who wrote the fi rst textbook of metabolic biochemistry in Germany. He studied cholesterol and bile acid balance in the biliary fi stula dog ( 1 ). During this time, bile acids were sold as liver tonics and laxatives, but there were no placebo-controlled studies showing effi cacy. Indeed, bile acids were considered by the medical profession to have no useful therapeutic properties. The tri-oxo derivative of cholic acid (called "dehydrocholic acid") was known to induce bile fl ow in animals ( 2 ), and was occasionally used to stimulate bile fl ow in patients; but again there were no controlled studies showing effi cacy in hepatobiliary disease.

show abstract

“…Chenodeoxycholic acid (CDCA, Chenossil kindly supplied by Giuliani Inc., Milan, Italy) is an effective treatment for dissolving cholesterol 1 Presented in part at the 11th Meeting of the European Association for the Study of the Liver, Copenhagen, August 1976 (Digestion 14: 476, 1976 gallstones (5,9,28): it is rapidly and com pletely absorbed and is effectively excreted by the liver (29). It appears to act by lowering biliary cholesterol secretion (1,21).…”

mentioning

confidence: 99%

Effect of Chenodeoxycholic Acid on Liver Structure and Function in Man: a Stereological and Biochemical Study

et al. 1980

View full text Add to dashboard Cite

Chenodeoxycholic acid (CDCA) is an effective treatment for dissolving gallstones but experimental studies have suggested that it might be hepatotoxic. The present study is concerned with a group of patients undergoing medical therapy for gallstones for periods of 30 days up to 14 months with CDCA (15 mg/kg/day). Routine functional tests, determination of some liver microsomal enzymes and stereological studies of the liver tissue have been performed and the data have been compared with those obtained before treatment. No significant changes were observed in the functional tests throughout the study. Also the microsomal mixed function oxidase system seemed unaffected by CDCA therapy. The histological features of the liver biopsies were not appreciably different from those observed prior to treatment. Although there were large interindividual variations, the volume density of parenchymal steatosis and of the lipocytes remained comparable in the same individual. The ultrastructural features noted in untreated subjects such as curled mitochondrial cristae, slight intracellular bile retention, increased surface density of the rough endoplasmic reticulum were still evident after 14 months of treatment. No additional changes were noted. These results show that no evidence of hepatotoxicity seems to develop in man under therapy with CDCA at the dose considered. But the structural abnormalities observed before treatment appear to persist even in subjects under long-term therapy.

show abstract

Liver structure and function in cholelithiasis: Effect of chenodeoxycholic acid

Cited by 70 publications

References 28 publications

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades

Effect of Chenodeoxycholic Acid on Liver Structure and Function in Man: a Stereological and Biochemical Study

Contact Info

Product

Resources

About